Abstract
We developed a facile synthesis process for producing optically active non-secosteroidal ligands (YR301-304), which are stereoisomers of LG190178, and evaluated their performance in transcriptional assays using mutant vitamin D receptor (VDR). It was found that all of them had stronger activities than the natural ligand 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. In particular, YR301 showed potent activity for both wild-type and mutant Arg274Leu VDR.
Keywords: Asymmetric reduction, vitamin D receptor, mutant vitamin D receptor, non-secosteroidal ligand, transcriptional assay, molecular modeling study
Letters in Organic Chemistry
Title: Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Volume: 8 Issue: 1
Author(s): Yosuke Demizu, Aki Nakatsu, Yukiko Sato, Shinobu Honzawa, Atsushi Yamashita, Takayuki Sugiura, Atsushi Kittaka, Shigeaki Kato, Haruhiro Okuda and Masaaki Kurihara
Affiliation:
Keywords: Asymmetric reduction, vitamin D receptor, mutant vitamin D receptor, non-secosteroidal ligand, transcriptional assay, molecular modeling study
Abstract: We developed a facile synthesis process for producing optically active non-secosteroidal ligands (YR301-304), which are stereoisomers of LG190178, and evaluated their performance in transcriptional assays using mutant vitamin D receptor (VDR). It was found that all of them had stronger activities than the natural ligand 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. In particular, YR301 showed potent activity for both wild-type and mutant Arg274Leu VDR.
Export Options
About this article
Cite this article as:
Demizu Yosuke, Nakatsu Aki, Sato Yukiko, Honzawa Shinobu, Yamashita Atsushi, Sugiura Takayuki, Kittaka Atsushi, Kato Shigeaki, Okuda Haruhiro and Kurihara Masaaki, Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor, Letters in Organic Chemistry 2011; 8 (1) . https://dx.doi.org/10.2174/157017811794557804
DOI https://dx.doi.org/10.2174/157017811794557804 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Retrocyclins: Using Past as Prologue
Current Protein & Peptide Science Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Reversion of Multidrug Resistance Using Self-Organized Nanoparticles Holding Both Doxorubicin and Targeting Moiety
Letters in Drug Design & Discovery Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Targeting BMP9-Promoted Human Osteosarcoma Growth by Inactivation of Notch Signaling
Current Cancer Drug Targets Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Automated Radiosynthesis and Molecular Docking Studies of Coumarin- Triazole Hybrid with fluorine-18: A feasibility study
Current Radiopharmaceuticals Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Characterizing the Relationship Between the Chemical Structures of Drugs and their Activities on Primary Cultures of Pediatric Solid Tumors
Current Medicinal Chemistry Alpha-Particle Microdosimetry
Current Radiopharmaceuticals Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Selective Thyroid Hormone Receptor Modulators
Current Topics in Medicinal Chemistry Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry